Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor : Fails In Late-Stage Trial For Breast Cancer Combo Treatment

08/04/2021 | 12:27am EDT


ę MT Newswires 2021
All news about POLYPHOR AG
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/15La Commission des OPA constate l'absence d'obligation de présenter une offre publique d..
DJ
10/15Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer ..
DJ
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
More news
Financials
Sales 2021 1,00 M 1,09 M 1,09 M
Net income 2021 -41,4 M -45,0 M -45,0 M
Net Debt 2021 76,8 M 83,6 M 83,6 M
P/E ratio 2021 -0,47x
Yield 2021 -
Capitalization 21,8 M 23,8 M 23,7 M
EV / Sales 2021 98,6x
EV / Sales 2022 5,66x
Nbr of Employees 52
Free-Float 82,3%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,77 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-78.28%24
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464